Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,374 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,072 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07724496 | Helicobacter Pylori Infection Status and Pathological Features for Predicting Gastric Cancer Biological Behavior and Prognosis: A Real-World Observational Study | recruiting | — | 1,500 | Chinese PLA General HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05376592 | Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma | recruiting | — | 100 | Wake Forest University Health SciencesOTHER | 1 | Jul 23, 2026 |
| clinicaltrials |
| NCT06796114 | Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab(PREDICT-HCC) | recruiting | N/A | 120 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07589205 | Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors | recruiting | Phase 1 | 493 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04970056 | Pancreatic Cancer Early Detection Consortium(PRECEDE) | recruiting | — | 20,000 | Arbor Research Collaborative for HealthOTHER | 11 | Jul 22, 2026 | clinicaltrials |
| NCT05208762 | A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | recruiting | Phase 1 | 714 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 11 | Jul 22, 2026 | clinicaltrials |
| NCT06131840 | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 914 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT06834126 | Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial | recruiting | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07318805 | A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 260 | PfizerINDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06796803 | Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) | recruiting | Phase 2 / Phase 3 | 398 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07710495 | Exercise to Improve Outcomes in Pancreatic Cancer(ExO-PanC) | recruiting | N/A | 60 | University of SurreyOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05092373 | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | recruiting | Phase 1 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05705492 | Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer | recruiting | Phase 2 | 66 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06207305 | A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06840977 | COLON ERDERLY LOW DOSE(CELOW) | recruiting | — | 51 | Matteo ClavarezzaOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07189195 | TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma | recruiting | Phase 1 | 52 | University of California, DavisOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07464756 | SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer | recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT01365169 | Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" | recruiting | N/A | 590 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06478719 | To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization | recruiting | Phase 1 / Phase 2 | 120 | Febico Biomedical Corp.INDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07010497 | A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma(IAPETUS) | recruiting | Phase 2 | 33 | Asan Medical CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07704489 | San Raffaele Registry on Liver Cancer | recruiting | — | 4,000 | IRCCS San RaffaeleOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05669339 | AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma | recruiting | Phase 2 | 12 | University of FloridaOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07700992 | A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring(PANXEON) | recruiting | — | 600 | Università Vita-Salute San RaffaeleOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04840264 | Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction | recruiting | Phase 2 | 79 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | recruiting | Phase 1 / Phase 2 | 29 | University of FloridaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05199259 | Multi-analyte Blood Test Clinical Trial(LIVER-1) | recruiting | — | 1,200 | Helio GenomicsINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06282809 | The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy(GANNON) | recruiting | N/A | 50 | HistoSonics, Inc.INDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07018947 | Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC(ASPIRE) | recruiting | Phase 2 | 90 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07518147 | A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment | recruiting | Phase 3 | 438 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07689851 | Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer | recruiting | Phase 2 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06314958 | Stage II/III Colorectal Cancer Recurrence(CENSURE) | recruiting | — | 400 | City of Hope Medical CenterOTHER | 3 | Jul 7, 2026 | clinicaltrials |
| NCT06342401 | Early Onset Colorectal Cancer Detection(ENCODE) | recruiting | — | 400 | City of Hope Medical CenterOTHER | 4 | Jul 7, 2026 | clinicaltrials |
| NCT06342414 | An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer(ELUCIDATE) | recruiting | — | 400 | City of Hope Medical CenterOTHER | 2 | Jul 7, 2026 | clinicaltrials |
| NCT06342440 | Early Detection of Advanced Adenomas and Colorectal Cancer(AACRC) | recruiting | — | 2,000 | City of Hope Medical CenterOTHER | 5 | Jul 7, 2026 | clinicaltrials |
| NCT06824363 | ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu | recruiting | Early Phase 1 | 34 | University of California, IrvineOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07224750 | A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer(MiGIC) | recruiting | — | 1,000 | City of Hope Medical CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04389632 | A Study of Sigvotatug Vedotin in Advanced Solid Tumors | recruiting | Phase 1 | 1,006 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 6, 2026 | clinicaltrials |
| NCT04634357 | ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma(ARYA-2) | recruiting | Phase 1 / Phase 2 | 12 | Eureka Therapeutics Inc.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 112 | Perspective TherapeuticsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07683845 | Patient-Derived Organoid-on-a-Chip Model for Personalized Prediction of Chemotherapy Efficacy in Pancreatic Cancer | recruiting | — | 164 | Beijing Daxiang Biotech Co., LtdINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06184152 | CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules | recruiting | N/A | 600 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06260943 | Targeted Navigation in Hepatocellular Carcinoma (HCC) | recruiting | N/A | 210 | University of MiamiOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04472767 | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | recruiting | Phase 2 | 35 | University of California, IrvineOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05530343 | Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance(SWAT-BE) | recruiting | N/A | 2,298 | University of Colorado, DenverOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07022015 | Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy(POPF) | recruiting | N/A | 100 | Minia UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07265271 | Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)(CENTINEL) | recruiting | — | 600 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07549399 | SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC(CRITⅡ) | recruiting | Phase 3 | 204 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 24, 2026source: clinicaltrials